Not everyone responds to the first depression treatment they try. That’s not a failure of care. It’s something clinicians anticipate and plan for. Depression is a condition with a lot of individual variation, and the path to meaningful relief often involves more than one step.
This article walks through how clinicians decide when something isn’t working, what adjustments they make, and when more advanced options, including ketamine therapy or other interventions, come into the picture.
Quick Answer Summary
Clinicians sequence depression treatment in a structured way, starting with first-line options like therapy and antidepressants, then adjusting through dose changes, switching, or augmentation before moving to advanced treatments such as TMS, ketamine therapy, or Spravato. Treatment decisions are based on response, symptom severity, side effects, and patient preferences, with ongoing monitoring guiding each step. This process ensures care remains personalized and evidence-based rather than one-size-fits-all.
First-Line Depression Treatment
Most people begin with evidence-based first-line options. Clinicians typically start by recommending psychotherapy, often cognitive behavioral therapy (CBT) or interpersonal therapy (IPT), antidepressant medications such as SSRIs or SNRIs, lifestyle changes, or some combination of these.
These starting points are well-studied and effective for a substantial portion of patients. They’re the foundation of most depression treatment plans precisely because they carry the best evidence for broad populations and tend to have manageable side effect profiles.
How Clinicians Know It’s Not Working
Before a clinician can decide a treatment isn’t working, they first must confirm it was given a fair chance.
According to NIMH’s depression guidance, antidepressants typically take four to eight weeks to show their full effect, and early improvements in sleep or appetite often precede shifts in mood. The VA/DoD Clinical Practice Guideline for Major Depressive Disorder specifies a minimum of four to six weeks of maximized monotherapy before a clinician reassesses the plan.
So, the first question isn’t “did it fail?” It’s “was the dose right, was it taken consistently, and was there enough time?” Once those boxes are checked, clinicians assess response in a more structured way. Tools like the PHQ-9, a standardized symptom checklist, help track severity over time rather than relying on memory or impression alone.
From there, clinicians categorize what they’re seeing: full response, partial response, no response, or response complicated by side effects. Each of those leads somewhere different.
Adjusting Before Escalating
A partial response doesn’t automatically mean it’s time to move on. Clinicians often work through several adjustments first.
That might mean increasing the dose, switching to a different antidepressant within the same class, adding a complementary medication, or pairing medication with therapy if therapy wasn’t already part of the picture. The VA/DoD guideline lays out these options explicitly:
- Switching to another antidepressant
- Switching to psychotherapy
- Augmenting with psychotherapy
- Augmenting with a second-generation antipsychotic
This kind of iteration is a normal part of psychiatric treatment, not a sign that the system has broken down. Clinicians may go through more than one permutation here before concluding that something more substantial needs to change.
Defining Treatment Resistance and Next Steps
If two or more adequate antidepressant trials haven’t produced sufficient relief, the clinical picture shifts. NIMH defines this scenario as treatment-resistant depression, or TRD, depression that doesn’t improve despite at least two antidepressants given at appropriate doses for appropriate durations.
TRD is a biological reality. It isn’t about effort, compliance, or outlook. Some people’s depression doesn’t respond the way initial treatment algorithms predict, and the evidence base reflects how common this is.
The STAR*D Level 1 study, one of the largest real-world depression trials in U.S. history, found that roughly one-third of participants reached full remission with their first treatment step, and about 10–15% more responded without achieving full remission. That means a meaningful portion of patients, more than half, didn’t fully respond to the first attempt.
At Level 2, approximately 1,439 people entered a next-step phase, and even there, the outcomes varied: Switching to a different antidepressant led to improvement in roughly one in four people, while augmenting with an additional medication helped about one in three reach remission in the augmentation arm.
The numbers show why sequenced psychiatric treatment exists and why clinicians don’t treat nonresponse as a dead end.
The Advanced Treatment Sequence
When standard adjustments haven’t been enough, clinicians begin considering a different tier of interventions. This is where options like ketamine therapy, transcranial magnetic stimulation (TMS), Spravato (esketamine), and electroconvulsive therapy (ECT) enter the picture.
TMS is generally considered after two or more adequate medication trials. Ketamine or esketamine is considered for augmentation after several adequate pharmacologic trials. ECT is typically reserved for the most severe presentations, like catatonia, psychotic depression, serious suicidality, or multiple prior treatment failures.
The decision isn’t just “what’s next,” but what makes sense for this patient. Someone who needs rapid relief may be a candidate for ketamine therapy earlier in the advanced-care sequence because of how quickly it can work. Someone who prefers to avoid medications may be a good fit for TMS. Sequencing depends on urgency, symptom profile, side-effect history, and patient preference.
Esketamine (Spravato) is worth noting specifically. The FDA expanded its approval of Spravato in 2025 to include monotherapy for treatment-resistant depression.
The updated label notes that Spravato was evaluated across six studies involving 1,709 adults with TRD, and because of risks including sedation and dissociation, it’s available only through a restricted REMS program and requires at least two hours of post-dose monitoring in a clinical setting. It’s effective, but it’s also tightly managed, which is exactly how advanced psychiatric care is supposed to work.
Ongoing Monitoring and Re-Sequencing
Depression treatment isn’t a straight line. A clinician doesn’t move from step one to step five and stay there. The plan keeps evolving based on what happens at each stage.
A 2023 PCORI OPTIMUM study focused on older adults with treatment-resistant depression found that augmenting with a second medication outperformed switching in step one of care. Close to 30% of participants reached remission through augmentation, roughly 10 percentage points higher than those who switched. But the same study flagged a safety difference between augmentation agents: Bupropion augmentation was associated with 0.55 falls per patient compared to 0.33 for aripiprazole augmentation. That kind of nuance, what works and at what cost, is exactly why re-assessment doesn’t stop after a treatment decision is made.
Partial responders may try combinations. Someone who’s had a limited response to one advanced option may shift to another. The measurement tools used earlier don’t disappear at this stage; they’re how clinicians know whether a new approach is doing something.
The Right Sequence Starts Here at Zeam
When initial depression treatment doesn’t produce the relief someone needs, it’s not a stop sign. It’s information, and it shapes the next step in a structured, personalized process that can include adjustments, augmentation, or more advanced options depending on where someone is in their care journey.
When standard treatments haven’t moved the needle, that’s when our team at Zeam gets to work. We see patients across the full range of care, including early-stage evaluation through Spravato, TMS, and ketamine therapy, and no two plans look the same. If you’re still searching for relief in Sacramento, Folsom, and Roseville, reach out today and let’s talk through what’s worth trying next.
Key Takeaways
- Depression treatment follows a step-by-step structure – Clinicians begin with first-line treatments like psychotherapy and antidepressants before moving to more advanced options when needed.¹
- A treatment must be given a fair trial before being changed – Antidepressants typically require 4–8 weeks to assess effectiveness, with guidelines recommending at least 4–6 weeks of adequate dosing before reassessment.¹²
- Clinicians use structured tools to measure response – Tools like the PHQ-9 help track symptom severity over time, guiding whether treatment is working or needs adjustment.
- Adjustments come before escalation – Before moving to advanced treatments, clinicians may increase dosage, switch medications, or use augmentation strategies such as combining therapy or additional medications.²
- Treatment-resistant depression is common – Failure to respond after two adequate antidepressant trials is defined as treatment-resistant depression, a well-recognized clinical condition.³
- Large studies show many patients need multiple steps – The STAR*D trial found only about one-third of patients achieved remission with first-line treatment, highlighting the need for sequenced care.⁴⁵
- Advanced treatments are introduced strategically – Options like TMS, ketamine therapy, Spravato, and ECT are considered based on symptom severity, urgency, and patient preference.²
- Spravato is tightly regulated and clinically supervised – Esketamine requires in-clinic administration with monitoring due to risks like sedation and dissociation, reflecting its role in advanced care.⁶⁷
- Treatment plans continue evolving over time – Depression care is dynamic, with clinicians re-evaluating and re-sequencing treatments based on response and safety considerations.
Citations
- National Institute of Mental Health – Depression Overview
https://www.nimh.nih.gov/sites/default/files/health/publications/depression/depression.pdf - VA/DoD Clinical Practice Guideline for Major Depressive Disorder
https://www.healthquality.va.gov/guidelines/MH/mdd/VADODMDDCPGFinal508.pdf - StatPearls – Treatment-Resistant Depression
https://www.ncbi.nlm.nih.gov/books/NBK620702/ - STAR*D Level 1 Results
https://www.nimh.nih.gov/funding/clinical-research/practical/stard/studylevel1results - STAR*D Level 2 Results
https://www.nimh.nih.gov/funding/clinical-research/practical/stard/level2results - FDA Approval Letter for Spravato (Esketamine)
https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2025/211243Orig1s016ltr.pdf - FDA Prescribing Information for Spravato
https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/211243s016lbl.pdf
